

# Sylvie Deuffic-Burban

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8732583/publications.pdf>

Version: 2024-02-01

68  
papers

2,476  
citations

201575

27  
h-index

197736

49  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3428  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling the hepatitis C virus epidemic in france. <i>Hepatology</i> , 1999, 29, 1596-1601.	3.6	190
2	Risk Factors for Hepatitis C Virus Transmission to Health Care Workers after Occupational Exposure: A European Case-Control Study. <i>Clinical Infectious Diseases</i> , 2005, 41, 1423-1430.	2.9	144
3	Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. <i>Journal of Viral Hepatitis</i> , 2007, 14, 107-115.	1.0	136
4	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: TableÂ1. <i>Gut</i> , 2015, 64, 1824-1833.	6.1	128
5	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	0.6	107
6	Impact of Drug Stock-Outs on Death and Retention to Care among HIV-Infected Patients on Combination Antiretroviral Therapy in Abidjan, CÃte d'Ivoire. <i>PLoS ONE</i> , 2010, 5, e13414.	1.1	106
7	Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2010, 5, e13132.	1.1	93
8	Blood-borne viruses in health care workers: Prevention and management. <i>Journal of Clinical Virology</i> , 2011, 52, 4-10.	1.6	88
9	Hepatitis C treatment as prevention of viral transmission and liverârelated morbidity in persons who inject drugs. <i>Hepatology</i> , 2016, 63, 1090-1101.	3.6	81
10	Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. <i>Journal of Hepatology</i> , 2006, 44, 455-461.	1.8	79
11	Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study. <i>BMC Infectious Diseases</i> , 2013, 13, 200.	1.3	75
12	Adjuvant Intraperitoneal 5-Fluorouracil in High-Risk Colon Cancer. <i>Annals of Surgery</i> , 2000, 231, 449-456.	2.1	73
13	Assessing the cost-effectiveness of hepatitis C screening strategies in France. <i>Journal of Hepatology</i> , 2018, 69, 785-792.	1.8	66
14	Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. <i>Journal of Viral Hepatitis</i> , 2002, 9, 114-122.	1.0	63
15	The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV-Infected Adults in CÃte D'Ivoire. <i>Antiviral Therapy</i> , 2007, 12, 543-551.	0.6	60
16	Comparing the public health burden of chronic hepatitis C and HIV infection in France. <i>Journal of Hepatology</i> , 2004, 40, 319-326.	1.8	59
17	Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). <i>Journal of Hepatology</i> , 2014, 61, 7-14.	1.8	57
18	Impact of Human Immunodeficiency Virus Type 1 Subtype on First-Line Antiretroviral Therapy Effectiveness. <i>Antiviral Therapy</i> , 2005, 10, 247-254.	0.6	56

#	ARTICLE	IF	CITATIONS
19	Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. <i>Journal of Viral Hepatitis</i> , 1999, 6, 411-413.	1.0	55
20	Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. <i>Hepatology</i> , 2014, 59, 1471-1481.	3.6	52
21	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , 2019, 5, 60-66.	0.3	49
22	Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. <i>Journal of Hepatology</i> , 2008, 49, 175-183.	1.8	46
23	Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. <i>Cancer</i> , 2018, 124, 1964-1972.	2.0	46
24	2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. <i>Liver International</i> , 2016, 36, 1442-1449.	1.9	36
25	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. <i>Clinical Infectious Diseases</i> , 2014, 58, 1064-1071.	2.9	34
26	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , 2019, 5, 60-66.	0.3	34
27	Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1197-1207.	1.0	32
28	Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. <i>Journal of Viral Hepatitis</i> , 2016, 23, 767-779.	1.0	27
29	Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. <i>HIV Medicine</i> , 2012, 13, 148-155.	1.0	25
30	How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. <i>Hepatology</i> , 2015, 62, 31-39.	3.6	25
31	Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. <i>Hepatology</i> , 2009, 50, 1351-1359.	3.6	24
32	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
33	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis. <i>Journal of Hepatology</i> , 2012, 57, 260-266.	1.8	22
34	Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. <i>Journal of Viral Hepatitis</i> , 2015, 22, 213-229.	1.0	22
35	Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling. <i>European Journal of Epidemiology</i> , 2007, 22, 737-744.	2.5	18
36	Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. <i>Statistical Methods in Medical Research</i> , 2009, 18, 233-252.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. <i>Gut</i> , 2012, 61, 290-296.	6.1	17
38	Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage. <i>PLoS ONE</i> , 2019, 14, e0215596.	1.1	17
39	Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. <i>Gut</i> , 2009, 58, 105-110.	6.1	15
40	Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: A modelling approach. <i>Digestive and Liver Disease</i> , 2014, 46, 157-163.	0.4	15
41	A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2315-2323.e6.	2.4	15
42	SPECIFIC ISOTYPE IMMUNE RESPONSE IN THE DIAGNOSIS OF HUMAN SCHISTOSOMIASIS PATHOLOGY?. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 202-205.	0.6	14
43	Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. <i>Aids</i> , 2008, 22, 1087-1089.	1.0	13
44	Natural polymorphisms in HIV-1 protease: Impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen. <i>Journal of Medical Virology</i> , 2008, 80, 1871-1879.	2.5	12
45	Hyperlactataemia During Antiretroviral Therapy: Incidences, Clinical Data and Treatment. <i>Therapie</i> , 2003, 58, 153-158.	0.6	10
46	Is the AIDS incubation time changing? A back-calculation approach. , 1999, 18, 1031-1047.		9
47	Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000. <i>European Journal of Epidemiology</i> , 2006, 21, 389-396.	2.5	8
48	ABCB1 Allele Polymorphism Is Associated with Virological Efficacy in Naïve HIV-Infected Patients on HAART Containing Nonboosted PIs But Not Boosted PIs. <i>HIV Clinical Trials</i> , 2008, 9, 192-201.	2.0	8
49	Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?. <i>Journal of Hepatology</i> , 2017, 66, 304-312.	1.8	8
50	Age and gender will survive to competing risks as fibrosis factors. <i>Gastroenterology</i> , 2005, 128, 519-520.	0.6	7
51	Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. <i>Gut</i> , 2021, 70, 1561-1569.	6.1	7
52	Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017. <i>Eurosurveillance</i> , 2021, 26, .	3.9	7
53	Specific isotype immune response in the diagnosis of human schistosomiasis pathology?. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 202-5.	0.6	7
54	It Is Time to Change the Paradigm for Hepatitis C Virus Testing. <i>Clinical Infectious Diseases</i> , 2012, 54, 1272-1274.	2.9	6

#	ARTICLE	IF	CITATIONS
55	Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw235.	0.4	6
56	Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: Clinical and economic impact. <i>PLOS Currents</i> , 2009, 1, RRN1121.	1.4	5
57	Expected increase in prevalence of HCV-related cirrhosis and its complications in the United States: No effect of current antiviral treatment coverage?. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 577-579.	0.9	4
58	Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription. <i>International Journal of STD and AIDS</i> , 2012, 23, 865-869.	0.5	4
59	Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable. <i>Gut</i> , 2015, 64, 1190-1191.	6.1	3
60	Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. <i>BMC Medical Research Methodology</i> , 2014, 14, 39.	1.4	2
61	Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study). <i>Journal of Hepatology</i> , 2020, 73, S797-S798.	1.8	2
62	A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. <i>Liver International</i> , 2021, 41, 91-100.	1.9	2
63	Mathematical modeling: A tool for selecting agents with complementary modes of action?. <i>Journal of Hepatology</i> , 2013, 59, 1346-1348.	1.8	1
64	Reply. <i>Hepatology</i> , 2016, 64, 1004-1006.	3.6	1
65	Reply. <i>Gastroenterology</i> , 2014, 147, 936-937.	0.6	0
66	Reply. <i>Hepatology</i> , 2017, 65, 2129-2130.	3.6	0
67	THU-297-Prediction of NAFLD progression according to duration of exposure to obesity and diabetes: New approach to adapt therapeutic and research strategies. <i>Journal of Hepatology</i> , 2019, 70, e291.	1.8	0
68	THU-391-Impact of early screening and treatment of hepatitis C virus and improvements in risk reduction on HCV transmission among HIV-infected men who have sex with men in France: A modeling approach. <i>Journal of Hepatology</i> , 2019, 70, e327.	1.8	0